Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

26 questions · 26 findings · 3 reviews

No studies found 1 · 3.8%GRADE not reported 0 · 0%Very low 1 · 3.8%Low 9 · 34.6%Moderate 12 · 46.2%High 3 · 11.5%

160/4.5 mcg BDF single inhaler therapy vs current best practice

Hospital admissions due to exacerbations: number of participants · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with current best practice (low certainty).

1 finding from 1 review

160/4.5 mcg BDF single inhaler therapy vs current best practice

Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy probably leads to lower patients with exacerbations treated with oral steroids compared with current best practice (moderate certainty).

1 finding from 1 review

160/4.5 mcg BDF single inhaler therapy vs current best practice

Fatal serious adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).

1 finding from 1 review

160/4.5 mcg BDF single inhaler therapy vs current best practice

Non‐fatal serious adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).

1 finding from 1 review

160/4.5 mcg BDF single inhaler therapy vs current best practice

Withdrawals due to adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).

1 finding from 1 review